追蹤
James Cheng-Chung WEI 魏正宗
James Cheng-Chung WEI 魏正宗
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital
在 csmu.edu.tw 的電子郵件地址已通過驗證 - 首頁
標題
引用次數
引用次數
年份
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
M Rudwaleit, D Van Der Heijde, R Landewé, J Listing, N Akkoc, J Brandt, ...
Annals of the rheumatic diseases 68 (6), 777-783, 2009
45422009
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
M Rudwaleit, D van der Heijde, R Landewé, N Akkoc, J Brandt, CT Chou, ...
Annals of the rheumatic diseases 70 (1), 25-31, 2011
19512011
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
JS Smolen, J Braun, M Dougados, P Emery, O FitzGerald, P Helliwell, ...
Annals of the rheumatic diseases 73 (1), 6-16, 2014
6182014
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
D van der Heijde, A Deodhar, JC Wei, E Drescher, D Fleishaker, ...
Annals of the rheumatic diseases 76 (8), 1340-1347, 2017
3662017
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological …
D van der Heijde, JCC Wei, M Dougados, P Mease, A Deodhar, ...
The Lancet 392 (10163), 2441-2451, 2018
3602018
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
D Baeten, M Østergaard, JCC Wei, J Sieper, P Järvinen, LS Tam, ...
Annals of the rheumatic diseases 77 (9), 1295-1302, 2018
3442018
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double‐blind …
M Dougados, D van der Heijde, J Sieper, J Braun, WP Maksymowych, ...
Arthritis & rheumatology 66 (8), 2091-2102, 2014
2532014
Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks
W Wang, CY Wang, SI Wang, JCC Wei
EClinicalMedicine 53, 2022
1892022
Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan
KH Yu, DY Chen, JH Chen, SY Chen, SM Chen, TT Cheng, SC Hsieh, ...
International journal of rheumatic diseases 21 (4), 772-787, 2018
1362018
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis
U Kiltz, D Van Der Heijde, A Boonen, N Akkoc, W Bautista-Molano, ...
Annals of the rheumatic diseases 77 (9), 1311-1317, 2018
1302018
Epigallocatechin gallate attenuates amyloid β-induced inflammation and neurotoxicity in EOC 13.31 microglia
JCC Wei, HC Huang, WJ Chen, CN Huang, CH Peng, CL Lin
European journal of pharmacology 770, 16-24, 2016
1222016
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo …
Y Tanaka, T Takeuchi, S Tanaka, A Kawakami, M Iwasaki, YW Song, ...
Annals of the rheumatic diseases 78 (10), 1320-1332, 2019
1122019
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 …
X Baraliakos, AJ Kivitz, AA Deodhar, J Braun, JC Wei, EM Delicha, ...
Clin Exp Rheumatol 36 (1), 50-55, 2018
1062018
Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese
CT Chou, AE Timms, JCC Wei, WC Tsai, BP Wordsworth, MA Brown
Annals of the rheumatic diseases 65 (8), 1106-1109, 2006
1002006
Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
EL Kneepkens, JCC Wei, MT Nurmohamed, KJ Yeo, CY Chen, ...
Annals of the rheumatic diseases 74 (2), 396-401, 2015
962015
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis
A Sepriano, R Landewé, D van der Heijde, J Sieper, N Akkoc, J Brandt, ...
Annals of the rheumatic diseases 75 (6), 1034-1042, 2016
942016
Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial.
JCC Wei, TW Chan, HS Lin, F Huang, CT Chou
The Journal of rheumatology 30 (12), 2627-2631, 2003
922003
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V …
M Dougados, JCC Wei, R Landewé, J Sieper, X Baraliakos, ...
Annals of the rheumatic diseases 79 (2), 176-185, 2020
912020
Association between hyperuricemia and metabolic syndrome: an epidemiological study of a labor force population in Taiwan
CY Wei, CC Sun, JCC Wei, HC Tai, CA Sun, CF Chung, YC Chou, PL Lin, ...
BioMed research international 2015 (1), 369179, 2015
822015
Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial
T Takeuchi, Y Tanaka, H Yamanaka, K Amano, R Nagamine, W Park, ...
Modern rheumatology 26 (1), 15-23, 2016
772016
系統目前無法執行作業,請稍後再試。
文章 1–20